Upcoming events – Novo takes aim at type 1 diabetes and Aslan wants to roar
Novo Nordisk hopes that its attempt to preserve beta cells will fare better than Caladrius’s, while Aslan tries its hand at DHODH inhibition.
Sillajen and Transgene bid to revive the oncolytic virus craze
The industry’s most advanced oncolytic virus project, Pexa-Vec, faces a make-or-break pivotal study readout.
AACR 2019 – Rubraca trial points to a place for Parps in pancreatic cancer
Encouraging early data from an academic trial of Clovis's Rubraca raise hopes that Parps could emerge as a more tolerable maintenance therapy for some pancreatic…
AACR 2019 – Guardant looks to its other liquid biopsy
With one cancer blood test established on the market Guardant is starting down the road to validating another – this time as a screening assay.
AACR 2019 – Xospata meets the conditions of its US approval
Survival data confirm the value of Astellas’s FLT3-targeting approach in acute myelogenous leukaemia.
AACR 2019 – Entinostat turns Syndax’s frown upside down
After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.
AACR 2019 – Vitrakvi relapse findings justify Bayer’s interest
The Vitrakvi follow-on LOXO-195 yields results backing both the rationale behind its development and Bayer’s decision to take on full rights.
AACR 2019 – Baylor sets the benchmark for Bellicum
A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.
AACR 2019 – Chi-Med has savolitinib filing in its sights
A patient death notwithstanding, Chi-Med reckons results from the Tatton study justify its US registration strategy.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.